Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
6.7M
Short interest
settlement 2026-10-15
7.3
Days to cover
-0.4 days vs prior
66.1%
Short share of volume
2026-11-02
2
Fails to deliver
settlement 2026-10-09
Tue 3 Nov
Next earnings
estimated date
-$10.6M
Insider flow, 90 days
0 buys, 9 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in MIRM is 6,663,045 shares, up 381,632 shares over the last month. Over the last 48 readings it ranged from 6,059,537 shares (30 May 2025) to 8,413,814 shares (30 April 2026). At the reported average volume of 913K shares a day that is 7.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/mirm" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 6,663,045 | -4.6% | 912,849 | 7.30 |
| 2026-09-30 | 6,985,385 | +11.2% | 910,920 | 7.67 |
| 2026-09-15 | 6,281,413 | +1.8% | 523,889 | 11.99 |
| 2026-08-31 | 6,171,979 | -4.9% | 467,192 | 13.21 |
| 2026-08-14 | 6,489,383 | -4.9% | 892,852 | 7.27 |
| 2026-07-31 | 6,823,706 | -6.2% | 566,260 | 12.05 |
| 2026-07-15 | 7,272,892 | -2.8% | 686,482 | 10.59 |
| 2026-06-30 | 7,483,286 | +8.3% | 1,491,921 | 5.02 |
| 2026-06-15 | 6,909,142 | +5.3% | 614,943 | 11.24 |
| 2026-05-29 | 6,561,290 | -19.9% | 828,272 | 7.92 |
| 2026-05-15 | 8,196,668 | -2.6% | 1,698,609 | 4.83 |
| 2026-04-30 | 8,413,814 | +2.4% | 573,704 | 14.67 |
| 2026-04-15 | 8,213,781 | +2.0% | 655,171 | 12.54 |
| 2026-03-31 | 8,050,414 | +7.9% | 1,176,318 | 6.84 |
| 2026-03-13 | 7,460,121 | -2.1% | 823,563 | 9.06 |
| 2026-02-27 | 7,623,019 | -5.2% | 781,878 | 9.75 |
| 2026-02-13 | 8,040,628 | +3.1% | 631,782 | 12.73 |
| 2026-01-30 | 7,795,041 | +2.7% | 816,048 | 9.55 |
| 2026-01-15 | 7,589,951 | -9.3% | 897,527 | 8.46 |
| 2025-12-31 | 8,363,319 | +13.4% | 920,464 | 9.09 |
| 2025-12-15 | 7,374,120 | -1.2% | 691,337 | 10.67 |
| 2025-11-28 | 7,464,991 | -2.6% | 410,314 | 18.19 |
| 2025-11-14 | 7,661,323 | +9.0% | 772,702 | 9.91 |
| 2025-10-31 | 7,027,185 | -4.9% | 419,481 | 16.75 |
| 2025-10-15 | 7,389,080 | +0.3% | 738,902 | 10.00 |
| 2025-09-30 | 7,365,570 | -1.8% | 884,454 | 8.33 |
| 2025-09-15 | 7,501,510 | +9.3% | 530,791 | 14.13 |
| 2025-08-29 | 6,861,339 | -0.9% | 902,984 | 7.60 |
| 2025-08-15 | 6,926,980 | +4.4% | 952,210 | 7.27 |
| 2025-07-31 | 6,634,186 | +0.8% | 308,415 | 21.51 |
| 2025-07-15 | 6,580,855 | +1.1% | 467,418 | 14.08 |
| 2025-06-30 | 6,512,657 | +4.7% | 474,256 | 13.73 |
| 2025-06-13 | 6,218,308 | +2.6% | 441,212 | 14.09 |
| 2025-05-30 | 6,059,537 | -3.6% | 304,549 | 19.90 |
| 2025-05-15 | 6,287,171 | +1.0% | 476,422 | 13.20 |
| 2025-04-30 | 6,225,486 | -0.8% | 358,787 | 17.35 |
| 2025-04-15 | 6,279,087 | -4.5% | 511,896 | 12.27 |
| 2025-03-31 | 6,578,301 | +4.7% | 438,022 | 15.02 |
| 2025-03-14 | 6,282,518 | -5.2% | 536,478 | 11.71 |
| 2025-02-28 | 6,626,034 | +0.3% | 666,028 | 9.95 |
| 2025-02-14 | 6,608,635 | +0.5% | 449,799 | 14.69 |
| 2025-01-31 | 6,573,423 | -1.1% | 531,270 | 12.37 |
| 2025-01-15 | 6,649,342 | +3.4% | 492,622 | 13.50 |
| 2024-12-31 | 6,430,289 | -6.0% | 375,524 | 17.12 |
| 2024-12-13 | 6,843,628 | +1.9% | 377,470 | 18.13 |
| 2024-11-29 | 6,717,759 | -3.7% | 380,924 | 17.64 |
| 2024-11-15 | 6,973,282 | +1.9% | 459,841 | 15.16 |
| 2024-10-31 | 6,845,267 | -2.2% | 270,583 | 25.30 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of MIRM volume is 66.1%, up 9.6 points over the last five sessions. Over the last 30 readings it ranged from 23.0% (6 October 2026) to 80.1% (23 October 2026). The latest reading is 17.1 points above the 30-session average of 48.9%, on 217K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 143K | 217K | 66.1% | 116 |
| 2026-10-30 | 116K | 329K | 35.1% | 1 |
| 2026-10-29 | 86K | 209K | 41.2% | 589 |
| 2026-10-28 | 109K | 206K | 52.7% | 52 |
| 2026-10-27 | 86K | 269K | 31.9% | 0 |
| 2026-10-26 | 80K | 141K | 56.5% | 145 |
| 2026-10-23 | 241K | 300K | 80.1% | 116,014 |
| 2026-10-22 | 79K | 116K | 68.0% | 174 |
| 2026-10-21 | 194K | 272K | 71.5% | 0 |
| 2026-10-20 | 186K | 254K | 73.0% | 620 |
| 2026-10-19 | 62K | 128K | 48.3% | 65 |
| 2026-10-16 | 77K | 162K | 47.5% | 0 |
| 2026-10-15 | 105K | 258K | 40.6% | 11 |
| 2026-10-14 | 101K | 438K | 23.1% | 47 |
| 2026-10-13 | 122K | 317K | 38.4% | 631 |
| 2026-10-12 | 286K | 509K | 56.3% | 0 |
| 2026-10-09 | 351K | 527K | 66.6% | 3,000 |
| 2026-10-08 | 115K | 251K | 45.9% | 220 |
| 2026-10-07 | 116K | 384K | 30.2% | 5,833 |
| 2026-10-06 | 107K | 467K | 23.0% | 184 |
| 2026-10-05 | 110K | 417K | 26.5% | 1,410 |
| 2026-10-02 | 265K | 484K | 54.7% | 86 |
| 2026-10-01 | 94K | 271K | 34.7% | 3,868 |
| 2026-09-30 | 243K | 417K | 58.4% | 484 |
| 2026-09-29 | 159K | 265K | 59.9% | 110 |
| 2026-09-28 | 395K | 626K | 63.1% | 9,519 |
| 2026-09-25 | 166K | 338K | 49.2% | 11,894 |
| 2026-09-24 | 99K | 334K | 29.7% | 12,050 |
| 2026-09-23 | 121K | 290K | 41.8% | 0 |
| 2026-09-22 | 112K | 207K | 54.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in MIRM is 2 shares, down 746 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (7 July 2026) to 241,590 shares (24 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 2 | $81.35 | $163 |
| 2026-10-08 | 748 | $80.64 | $60K |
| 2026-10-07 | 116 | $79.25 | $9K |
| 2026-09-30 | 26,924 | $87.54 | $2.4M |
| 2026-09-23 | 8,767 | $91.39 | $801K |
| 2026-09-22 | 44,759 | $92.00 | $4.1M |
| 2026-09-21 | 32,778 | $91.83 | $3.0M |
| 2026-09-18 | 37,524 | $98.82 | $3.7M |
| 2026-09-10 | 27 | $98.30 | $3K |
| 2026-09-09 | 17,137 | $99.53 | $1.7M |
| 2026-08-24 | 30 | $96.31 | $3K |
| 2026-08-18 | 2 | $99.83 | $200 |
| 2026-07-31 | 72 | $112.59 | $8K |
| 2026-07-28 | 226,091 | $114.20 | $25.8M |
| 2026-07-27 | 228,372 | $113.03 | $25.8M |
| 2026-07-24 | 241,590 | $114.36 | $27.6M |
| 2026-07-20 | 58 | $118.86 | $7K |
| 2026-07-16 | 21 | $121.00 | $3K |
| 2026-07-09 | 899 | $128.57 | $116K |
| 2026-07-07 | 2 | $121.91 | $244 |
| 2026-07-01 | 8 | $117.07 | $937 |
| 2026-06-30 | 6,236 | $123.00 | $767K |
| 2026-06-29 | 15,591 | $123.77 | $1.9M |
| 2026-06-16 | 140 | $101.00 | $14K |
| 2026-06-12 | 8,012 | $99.54 | $798K |
| 2026-06-08 | 8,329 | $93.48 | $779K |
| 2026-06-03 | 70 | $92.17 | $6K |
| 2026-06-02 | 53 | $96.33 | $5K |
| 2026-05-27 | 50 | $98.90 | $5K |
| 2026-05-26 | 298 | $98.62 | $29K |
Insider trades
SEC Form 4, newest first. JSONInsiders at MIRM reported 9 open-market sells worth $10.6M in the last 90 days and no open-market buys. Latest filing: Howe Jolanda (SVP, GLOBAL CONTROLLER) on 2026-10-16.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Exercise or conversion | 16K | $19.24 | $310K | 17K |
| 2026-10-06 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 7K | $15.87 | $109K | 207K |
| 2026-10-06 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 5K | $19.19 | $102K | 200K |
| 2026-09-14 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 10K | $98.37 | $978K | 45K |
| 2026-09-11 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Exercise or conversion | 18K | price not stated in the filing | not stated | 55K |
| 2026-09-02 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 658 | $100.00 | $66K | 616 |
| 2026-09-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 22K | $98.91 | $2.1M | 194K |
| 2026-09-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 8K | $98.08 | $815K | 216K |
| 2026-09-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 30K | $2.94 | $88K | 224K |
| 2026-08-18 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 40K | $100.00 | $4.0M | 1K |
| 2026-08-18 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Exercise or conversion | 40K | $6.27 | $251K | 41K |
| 2026-08-11 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 6K | $99.90 | $600K | 36K |
| 2026-08-10 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 2K | $100.14 | $230K | 194K |
| 2026-08-10 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 6K | $99.25 | $597K | 197K |
| 2026-08-10 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 12K | $98.51 | $1.2M | 203K |
| 2026-08-10 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 20K | $2.94 | $59K | 214K |
| 2026-08-03 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 2K | $105.29 | $194K | 1K |
| 2026-07-06 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 2K | $124.79 | $213K | 194K |
| 2026-07-06 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 2K | $123.74 | $244K | 196K |
| 2026-07-06 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 4K | $122.34 | $512K | 198K |
| 2026-07-06 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 12K | $121.65 | $1.5M | 202K |
| 2026-07-06 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 20K | $2.94 | $59K | 214K |
| 2026-07-06 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 300 | $124.94 | $37K | 42K |
| 2026-07-06 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 528 | $123.84 | $65K | 42K |
| 2026-07-06 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 1K | $122.43 | $128K | 43K |
| 2026-07-06 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 3K | $121.67 | $380K | 44K |
| 2026-07-01 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 3K | $120.00 | $327K | 3K |
| 2026-06-17 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 3K | $101.95 | $264K | 6K |
| 2026-06-09 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Exercise or conversion | 2K | $26.49 | $63K | 47K |
| 2026-06-08 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 2K | $95.12 | $149K | 45K |
| 2026-06-08 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 1K | $93.95 | $110K | 46K |
| 2026-06-08 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 2K | $92.84 | $210K | 48K |
| 2026-06-05 | Radovich Peter | PRESIDENT AND COO | Exercise or conversion | 17K | $19.19 | $326K | 57K |
| 2026-06-01 | Ramasastry Saira | Director | Sell | 4K | $100.00 | $398K | 0 |
| 2026-06-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 883 | $99.66 | $88K | 194K |
| 2026-06-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 1K | $98.20 | $100K | 195K |
| 2026-06-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 2K | $97.56 | $192K | 196K |
| 2026-06-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 7K | $96.15 | $666K | 198K |
| 2026-06-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 17K | $95.34 | $1.6M | 205K |
| 2026-06-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 3K | $94.64 | $246K | 222K |
| 2026-06-01 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 30K | $2.94 | $88K | 224K |
| 2026-05-29 | Fischer Laurent | Director | Exercise or conversion | 4K | price not stated in the filing | not stated | 11K |
| 2026-05-29 | Ramasastry Saira | Director | Exercise or conversion | 4K | price not stated in the filing | not stated | 4K |
| 2026-05-29 | Cardon Lon | Director | Exercise or conversion | 4K | price not stated in the filing | not stated | 10K |
| 2026-05-29 | Walbert Timothy P | Director | Exercise or conversion | 4K | price not stated in the filing | not stated | 10K |
| 2026-05-15 | Ramasastry Saira | Director | Sell | 2K | $109.47 | $219K | 0 |
| 2026-05-15 | Ramasastry Saira | Director | Exercise or conversion | 2K | $23.51 | $47K | 2K |
| 2026-04-15 | Ramasastry Saira | Director | Sell | 2K | $96.90 | $194K | 0 |
| 2026-04-15 | Ramasastry Saira | Director | Exercise or conversion | 2K | $23.51 | $47K | 2K |
| 2026-03-16 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 41K | $91.98 | $3.8M | 194K |
| 2026-03-16 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 5K | $91.98 | $435K | 8K |
| 2026-03-16 | Radovich Peter | PRESIDENT AND COO | Sell | 17K | $91.98 | $1.5M | 40K |
| 2026-03-16 | Quan Joanne | CHIEF MEDICAL OFFICER | Sell | 7K | $91.98 | $670K | 19K |
| 2026-03-16 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 7K | $91.98 | $670K | 50K |
| 2026-03-16 | Ramasastry Saira | Director | Sell | 2K | $90.76 | $182K | 0 |
| 2026-03-16 | Ramasastry Saira | Director | Exercise or conversion | 2K | $23.51 | $47K | 2K |
| 2026-03-15 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 50K | price not stated in the filing | not stated | 235K |
| 2026-03-15 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 25K | price not stated in the filing | not stated | 185K |
| 2026-03-15 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Exercise or conversion | 3K | price not stated in the filing | not stated | 7K |
| 2026-03-15 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Exercise or conversion | 6K | price not stated in the filing | not stated | 13K |
| 2026-03-15 | Radovich Peter | PRESIDENT AND COO | Exercise or conversion | 7K | price not stated in the filing | not stated | 34K |
| 2026-03-15 | Radovich Peter | PRESIDENT AND COO | Exercise or conversion | 23K | price not stated in the filing | not stated | 57K |
| 2026-03-15 | Quan Joanne | CHIEF MEDICAL OFFICER | Exercise or conversion | 13K | price not stated in the filing | not stated | 26K |
| 2026-03-15 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Exercise or conversion | 13K | price not stated in the filing | not stated | 57K |
| 2026-03-06 | Radovich Peter | PRESIDENT AND COO | Exercise or conversion | 6K | $15.87 | $94K | 27K |
| 2026-02-13 | Ramasastry Saira | Director | Sell | 2K | $102.09 | $204K | 0 |
| 2026-02-13 | Ramasastry Saira | Director | Exercise or conversion | 2K | $23.51 | $47K | 2K |
| 2026-02-02 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 968 | $103.30 | $100K | 5K |
| 2026-02-02 | Radovich Peter | PRESIDENT AND COO | Sell | 3K | $103.30 | $272K | 21K |
| 2026-02-02 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 9K | $103.30 | $941K | 160K |
| 2026-01-31 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Exercise or conversion | 2K | price not stated in the filing | not stated | 5K |
| 2026-01-26 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 7K | $96.19 | $657K | 169K |
| 2026-01-26 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 842 | $96.19 | $81K | 4K |
| 2026-01-26 | Radovich Peter | PRESIDENT AND COO | Sell | 3K | $96.19 | $302K | 23K |
| 2026-01-26 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 1K | $96.19 | $101K | 44K |
| 2026-01-23 | Heron Patrick J | Director | Buy | 131K | $68.48 | $9.0M | 459K |
| 2026-01-23 | Heron Patrick J | Director | Other transaction | 159K | price not stated in the filing | not stated | 328K |
| 2026-01-23 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 13K | price not stated in the filing | not stated | 176K |
| 2026-01-23 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Exercise or conversion | 2K | price not stated in the filing | not stated | 5K |
| 2026-01-23 | Radovich Peter | PRESIDENT AND COO | Exercise or conversion | 6K | price not stated in the filing | not stated | 26K |
| 2026-01-23 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Exercise or conversion | 3K | price not stated in the filing | not stated | 45K |
| 2026-01-22 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 7K | $93.33 | $662K | 164K |
| 2026-01-22 | Radovich Peter | PRESIDENT AND COO | Sell | 2K | $93.33 | $222K | 21K |
| 2026-01-22 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 1K | $93.33 | $133K | 42K |
| 2026-01-22 | Quan Joanne | CHIEF MEDICAL OFFICER | Sell | 2K | $93.33 | $170K | 13K |
| 2026-01-22 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 926 | $93.33 | $86K | 3K |
| 2026-01-21 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 13K | price not stated in the filing | not stated | 171K |
| 2026-01-21 | Radovich Peter | PRESIDENT AND COO | Exercise or conversion | 4K | price not stated in the filing | not stated | 23K |
| 2026-01-21 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Exercise or conversion | 3K | price not stated in the filing | not stated | 44K |
| 2026-01-21 | Quan Joanne | CHIEF MEDICAL OFFICER | Exercise or conversion | 3K | price not stated in the filing | not stated | 15K |
| 2026-01-21 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Exercise or conversion | 2K | price not stated in the filing | not stated | 4K |
| 2026-01-20 | Quan Joanne | CHIEF MEDICAL OFFICER | Sell | 7K | $90.27 | $624K | 11K |
| 2026-01-16 | Quan Joanne | CHIEF MEDICAL OFFICER | Exercise or conversion | 13K | price not stated in the filing | not stated | 18K |
| 2026-01-15 | Ramasastry Saira | Director | Sell | 2K | $90.99 | $182K | 0 |
| 2026-01-15 | Ramasastry Saira | Director | Exercise or conversion | 2K | $23.51 | $47K | 2K |
| 2025-12-31 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Gift | 21K | $0.00 | $0 | 188K |
| 2025-12-22 | Ramasastry Saira | Director | Sell | 5K | $80.00 | $400K | 0 |
| 2025-12-22 | Ramasastry Saira | Director | Exercise or conversion | 5K | $23.51 | $118K | 5K |
| 2025-12-19 | GREY MICHAEL G | Director | Sell | 50K | $78.00 | $3.9M | 0 |
| 2025-12-19 | GREY MICHAEL G | Director | Exercise or conversion | 50K | $2.94 | $147K | 50K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON36 Form 144 notices on file for MIRM worth $40.4M at the prices reported; 6 in the last 90 days worth $10.6M. Latest: ERIC BJERKHOLT filed on 2026-09-15 to sell 9,943 shares ($978K) from 2026-09-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-15 | ERIC BJERKHOLTOfficer | 10K | $978K | 0.015% | 2026-09-14 | Morgan Stanley Smith Barney LLC |
| 2026-09-02 | JOLANDA MARIE HOWEOfficer | 658 | $66K | 0.001% | 2026-09-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-01 | CHRISTOPHER PEETZOfficer, Director | 30K | $3.0M | 0.046% | 2026-09-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-18 | JOLANDA MARIE HOWEOfficer | 40K | $4.0M | 0.062% | 2026-08-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-11 | ERIC BJERKHOLTOfficer | 6K | $600K | 0.009% | 2026-08-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-10 | CHRISTOPHER PEETZOfficer, Director | 20K | $2.0M | 0.031% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-03 | JOLANDA MARIE HOWEOfficer | 2K | $194K | 0.003% | 2026-08-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-06 | CHRISTOPHER PEETZOfficer, Director | 20K | $2.4M | 0.033% | 2026-07-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-06 | ERIC BJERKHOLTOfficer | 5K | $611K | 0.008% | 2026-07-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | JOLANDA MARIE HOWEOfficer | 3K | $327K | 0.004% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-17 | JOLANDA MARIE HOWEOfficer | 3K | $264K | 0.004% | 2026-06-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-08 | ERIC BJERKHOLTOfficer | 5K | $469K | 0.008% | 2026-06-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | CHRISTOPHER PEETZOfficer, Director | 30K | $2.9M | 0.049% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | SAIRA RAMASASTRYDirector | 4K | $398K | 0.007% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-15 | SAIRA RAMASASTRYDirector | 2K | $219K | 0.003% | 2026-05-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-15 | SAIRA RAMASASTRYDirector | 2K | $194K | 0.003% | 2026-04-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-17 | Joanne QuanOfficer | 7K | $675K | 0.012% | 2026-03-16 | Morgan Stanley Smith Barney LLC |
| 2026-03-17 | Peter RadovichOfficer | 17K | $1.5M | 0.027% | 2026-03-16 | Morgan Stanley Smith Barney LLC |
| 2026-03-17 | Christopher PeetzOfficer, Director | 41K | $3.8M | 0.068% | 2026-03-16 | Morgan Stanley Smith Barney LLC |
| 2026-03-17 | Jolanda HoweOfficer | 5K | $438K | 0.008% | 2026-03-16 | Morgan Stanley Smith Barney LLC |
| 2026-03-17 | ERIC BJERKHOLTOfficer | 7K | $675K | 0.012% | 2026-03-16 | Morgan Stanley Smith Barney LLC |
| 2026-03-16 | SAIRA RAMASASTRYDirector | 2K | $182K | 0.003% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-13 | SAIRA RAMASASTRYDirector | 2K | $204K | 0.004% | 2026-02-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | Peter RadovichOfficer | 3K | $273K | 0.005% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Christopher PeetzOfficer, Director | 9K | $945K | 0.018% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-02-02 | Jolanda HoweOfficer | 968 | $100K | 0.002% | 2026-02-02 | Morgan Stanley Smith Barney LLC |
| 2026-01-28 | Peter RadovichOfficer | 3K | $305K | 0.006% | 2026-01-26 | Morgan Stanley Smith Barney LLC |
| 2026-01-28 | Christopher PeetzOfficer, Director | 7K | $662K | 0.013% | 2026-01-26 | Morgan Stanley Smith Barney LLC |
| 2026-01-28 | Jolanda HoweOfficer | 842 | $82K | 0.002% | 2026-01-26 | Morgan Stanley Smith Barney LLC |
| 2026-01-28 | ERIC BJERKHOLTOfficer | 1K | $102K | 0.002% | 2026-01-26 | Morgan Stanley Smith Barney LLC |
| 2026-01-15 | SAIRA RAMASASTRYDirector | 2K | $182K | 0.004% | 2026-01-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-22 | SAIRA RAMASASTRYDirector | 5K | $400K | 0.010% | 2025-12-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-19 | MICHAEL GREYDirector | 50K | $3.9M | 0.097% | 2025-12-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-18 | SAIRA RAMASASTRYDirector | 2K | $139K | 0.004% | 2025-12-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | MICHAEL GREYDirector | 50K | $3.7M | 0.097% | 2025-12-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-21 | MICHAEL GREYDirector | 50K | $3.5M | 0.097% | 2025-11-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON10 holders report 5% or more of MIRM in their latest filing, 5 on Schedule 13D (active intent). The largest reported stake is JANUS HENDERSON GROUP PLC at 11.8% of the class (6,065,308 shares), filed 2026-02-17 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 10 | JANUS HENDERSON GROUP Ltd.parent holding company | 5.9M | 9.7% | 2026-06-30 |
| 2026-08-06 | 13G | FMR LLCparent holding company | 3.8M | 6.2% | 2026-06-30 |
| 2026-08-06 | 13G | Abigail P. Johnsonindividual | 3.8M | 6.2% | 2026-06-30 |
| 2026-04-27 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 3.5M | 5.7% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 7 | JANUS HENDERSON GROUP PLCparent holding company | 6.1M | 11.8% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Finny Kuruvilla, M.D. Ph. D.parent holding company, individual | 2.1M | 4.1% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Eventide Asset Management, LLCinvestment adviser | 2.1M | 4.1% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Robin C. Johnparent holding company, individual | 2.1M | 4.1% | 2025-12-31 |
| 2026-01-27 | 13D/Ano. 8 | Patrick J. Heronindividual | 4.1M | 6.8% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | James N. Topperindividual | 4.0M | 6.7% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | Frazier Life Sciences IX, L.P.partnership | 3.6M | 5.9% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLS IX, L.P.partnership | 3.6M | 5.9% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLS IX, L.L.C.other entity | 3.6M | 5.9% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLSP, L.P.partnership | 2.5M | 4.2% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | Frazier Life Sciences Public Fund, L.P.partnership | 2.5M | 4.2% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLSP, L.L.C.other entity | 2.5M | 4.2% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLS XI, L.P.partnership | 1.1M | 1.8% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | Frazier Life Sciences XI, L.P.partnership | 1.1M | 1.8% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLS XI, L.L.C.other entity | 1.1M | 1.8% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLS X, L.L.C.other entity | 459K | 0.8% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLS X, L.P.partnership | 459K | 0.8% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | Frazier Life Sciences X, L.P.partnership | 459K | 0.8% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLS XII, L.L.C.other entity | 63K | 0.1% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | Frazier Life Sciences XII, L.P.partnership | 63K | 0.1% | 2026-01-23 |
| 2026-01-27 | 13D/Ano. 8 | FHMLS XII, L.P.partnership | 63K | 0.1% | 2026-01-23 |
| 2025-11-14 | 13G/Ano. 2 | LAMPERT MARK Nindividual | 1.5M | 3.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF INC/ILcorporation | 1.5M | 3.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF PARTNERS L P/ILinvestment adviser, partnership | 1.5M | 3.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF GP HOLDINGS LLCother entity | 1.4M | 2.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 773K | 1.5% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF I GP LLCother entity | 773K | 1.5% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF II GP LLCother entity | 611K | 1.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 611K | 1.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Biotechnology Value Trading Fund OS LPpartnership | 82K | 0.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF Partners OS Ltd.corporation | 82K | 0.2% | 2025-09-30 |
13F holders
Tracked managers holding MIRM at their latest 13F. JSON6 of the 30 tracked managers held MIRM at their latest 13F, $160.1M in total at quarter-end prices. Two Sigma Investments is the largest at $80.8M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 690K | $80.8M | 0.06% | -85K |
| Renaissance Technologies | 2026-06-30 | 442K | $51.8M | 0.07% | -140K |
| Millennium Management | 2026-06-30 | 96K | $11.3M | 0.00% | -272K |
| Fisher Asset Management | 2026-06-30 | 82K | $9.7M | 0.00% | -11K |
| AQR Capital Management | 2026-06-30 | 29K | $3.4M | 0.00% | -3K |
| D. E. Shaw & Co. | 2026-06-30 | 28K | $3.3M | 0.00% | -140K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Mirum Pharmaceuticals reported revenue of $176.2M, up 37.9% from the same quarter a year earlier, and net loss of $67.2M (-1.06 diluted EPS). In FY 2025 it generated $55.8M of operating cash flow.
- Cash
- $330.7M
- Equity
- -$10.4M
- Total assets
- $1.04B
- Shares outstanding
- 64,932,203
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $176.2M | -$67.2M | -38.1% | -1.06 |
| Q1 FY 2026 | 2026-03-31 | $159.9M | -$790.2M | -494.2% | -13.43 |
| Q4 FY 2025derived | 2025-12-31 | $148.9M | -$5.7M | -3.8% | n/a |
| Q3 FY 2025 | 2025-09-30 | $133.0M | $2.9M | 2.2% | 0.05 |
| Q2 FY 2025 | 2025-06-30 | $127.8M | -$5.9M | -4.6% | -0.12 |
| Q1 FY 2025 | 2025-03-31 | $111.6M | -$14.7M | -13.2% | -0.30 |
| Q4 FY 2024derived | 2024-12-31 | $99.4M | -$23.8M | -23.9% | n/a |
| Q3 FY 2024 | 2024-09-30 | $90.4M | -$14.2M | -15.8% | -0.30 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $521.3M | -$23.4M | $55.8M | $954K | n/a | n/a |
| FY 2024 | 2024-12-31 | $336.9M | -$87.9M | $10.3M | $993K | n/a | n/a |
| FY 2023 | 2023-12-31 | $186.4M | -$163.4M | -$70.9M | $109K | n/a | n/a |
| FY 2022 | 2022-12-31 | $77.1M | -$135.7M | -$120.1M | $278K | n/a | n/a |
| FY 2021 | 2021-12-31 | $19.1M | -$84.0M | -$132.8M | $24K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Mirum Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Mirum Pharmaceuticals (MIRM), SEC CIK 1759425, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-15.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-16.JSON and CSV
- Company record
- EDGAR filing index for CIK 1759425Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of MIRM is sold short?
6,663,045 shares were held short at the 2026-10-15 settlement, 7.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is MIRM's daily short volume?
On 2026-11-02, 143,197 of the 216,714 MIRM shares reported to FINRA were sold short, 66.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does MIRM have fails to deliver?
The SEC's latest file shows 2 MIRM shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are MIRM insiders buying or selling?
Insiders at MIRM reported 9 open-market sells worth $10.6M in the last 90 days and no open-market buys. Latest filing: Howe Jolanda (SVP, GLOBAL CONTROLLER) on 2026-10-16.
Have MIRM insiders filed to sell?
36 Form 144 notices on file for MIRM worth $40.4M at the prices reported; 6 in the last 90 days worth $10.6M. Latest: ERIC BJERKHOLT filed on 2026-09-15 to sell 9,943 shares ($978K) from 2026-09-14.
Who owns 5% or more of MIRM?
10 holders report 5% or more of MIRM in their latest filing, 5 on Schedule 13D (active intent). The largest reported stake is JANUS HENDERSON GROUP PLC at 11.8% of the class (6,065,308 shares), filed 2026-02-17 for an event on 2025-12-31.
What did MIRM report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Mirum Pharmaceuticals reported revenue of $176.2M, up 37.9% from the same quarter a year earlier, and net loss of $67.2M (-1.06 diluted EPS). In FY 2025 it generated $55.8M of operating cash flow.
Which tracked 13F managers own MIRM?
6 of the 30 tracked 13F managers held MIRM shares at their latest filing, $160.1M in all. The largest: Two Sigma Investments (690K shares, $80.8M), Renaissance Technologies (442K shares, $51.8M), Izzy Englander's Millennium Management (96K shares, $11.3M), Ken Fisher's Fisher Asset Management (82K shares, $9.7M), Cliff Asness's AQR Capital Management (29K shares, $3.4M), D. E. Shaw & Co. (28K shares, $3.3M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.